Loading...
Intellipharmaceutics International Inc.
IPCIF•PNK
Healthcare
Biotechnology
$0.15
$0.00(0.00%)

Financial performance has remained strong, with revenue growing from $29682.00 in Q4 2023 to $68718.00 in Q3 2024. Gross profit continued to perform well, with margins at -1171% in the latest quarter. Operating income reached -$1.79M in Q3 2024, holding a steady -2601% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$1.75M. Net income dropped to -$1.89M, keeping EPS at -$0.06. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan